AC Immune announces presentation of morADC at AAIC 2024

AC Immune unveiled a novel class of neurodegenerative disease-fighting drug-candidates called morADC in an oral presentation at the annual Alzheimer’s Association International Conference, AAIC 2024, taking place from July 28 – August 1, 2024, in Philadelphia, PA. Dr. Madiha Derouazi, Chief Scientific Officer of AC Immune, presented the characterization and in vitro efficacy of morADC for the first time. The talk, entitled “A new class of neurodegenerative disease-fighting drugs: morADC”, showed that: morADC are designed for CNS applications capable of addressing important targets including Abeta, Tau and a-synuclein; morADC enable single or dual-targeting strategies to deliver combination therapy in a single therapeutic agent; single-targeting morADC show significant synergistic anti-aggregation effects compared to the parental molecules; dual-targeting morADC show significantly enhanced anti-aggregation effects compared to the parental molecules; additionally, conjugation of brain-penetrant Morphomers with a monoclonal antibody can multiply antibody brain exposure in comparison to the parent antibody alone